Angiotensin II-induced Hypertension Model

Hypertension is a cardiovascular syndrome characterized primarily by elevated systemic arterial pressure, classified into primary hypertension and secondary hypertension. Primary hypertension accounts for over 90% of cases, with its etiology remaining unclear and associated with multifactorial interactions including genetic and environmental factors (e.g., high-salt diet, obesity, and stress). Secondary hypertension is caused by specific underlying diseases. The pathogenesis involves abnormalities in neural regulation, renal dysfunction, and vascular structural changes. Epidemiological studies indicate that the prevalence of hypertension increases with age, with a global prevalence rate of approximately 30%-40%.

 

Angiotensin II significantly elevates blood pressure by constricting blood vessels, stimulating aldosterone secretion, and enhancing sympathetic nervous activity. Hypertensive phenotypes can be induced in mice by implanting Angiotensin II (AngII)-loaded osmotic mini-pumps. Hypertensive phenotypes can then be assessed by monitoring blood pressure non-invasively via the tail-cuff method, quantifying vascular wall thickness through H&E staining, and assessing cardiac fibrosis using Masson staining.


Experimental Design and Example Data


1. Study design


1.png

Figure 1. Study design.

 

2. AngII elevation of blood pressure


2.png

Figure 2. (a) Body weight. (b) D14 systolic blood pressure. (c) H&E staining of the thoracic aorta and statistical analysis of vascular wall thickness. (Data are presented as Mean±SD, n = 6-8 per group,***denoted p<0.001).  

 

3.  AngII induced myocardial hypertrophy and injury



3.png

Figure 3. (a) Echocardiographic analysis revealed that AngII infusion in mice led to increased interventricular septum (IVS) and left ventricular posterior wall (LVPW) thickness, reduced left ventricular volume, and decreased cardiac output, demonstrating concentric hypertrophy. (b) Masson staining of cardiac tissue, with blue-stained areas indicating fibrosis. (c) Heart weight/ tibia length. (Data are presented as Mean±SD, n = 6-8 per group, *,**,***denoted p<0.05,p<0.01,p<0.001, respectively).  

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.